Update on Advanced Anti-CD20 Therapeutics to Improve Outcomes for Patients with Multiple Sclerosis

Update on Advanced Anti-CD20 Therapeutics to Improve Outcomes for Patients with Multiple Sclerosis is organized by AcademicCME.

Program Dates: Apr 5, 2024 - Apr 4, 2025

Description:
This CME program will highlight updates in the multiple sclerosis treatment landscape, including anti-CD20 therapeutics. The expert faculty, Dr. Grace Gombolay, will first utilize a case-based format to review current guidelines as well as the typical clinical course in multiple sclerosis. Following, recent clinical trial data of both B-cell depleting and anti-CD20 therapeutics will be analyzed, along with the implications for clinical practice. The expert faculty will conclude with an overview of future emerging therapies in multiple sclerosis, as well as practical tips for administering effective patient education to improve outcomes and quality of life.

Learning Objectives:

• Review recent efficacy and safety data for anti-CD20 therapeutics to treat patients with multiple sclerosis
• Recognize the current unmet needs of patients with MS and the role of anti-CD20 therapeutics to improve outcomes for these patients.